Ginkgo Bioworks (DNA) Stock Forecast, Price Target & Predictions
DNA Stock Forecast
Ginkgo Bioworks stock forecast is as follows: an average price target of $7.34 (represents a 16.14% upside from DNA’s last price of $6.32) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
DNA Price Target
The average price target for Ginkgo Bioworks (DNA) is $7.34 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $4.35. This represents a potential 16.14% upside from DNA's last price of $6.32.
DNA Analyst Ratings
According to 5 Wall Street analysts, Ginkgo Bioworks's rating consensus is 'Buy'. The analyst rating breakdown for DNA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 1 'Hold' (20.00%), 2 'Sell' (40.00%), and 0 'Strong Sell' (0.00%).
Ginkgo Bioworks Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 23, 2024 | Mark Massaro | BTIG | $7.00 | $8.30 | -15.66% | 10.76% |
| Nov 29, 2022 | - | Berenberg Bank | $6.00 | $1.84 | 226.09% | -5.06% |
| Aug 16, 2022 | - | BTIG | $6.00 | $3.74 | 60.43% | -5.06% |
| Jun 16, 2022 | - | Jefferies | $4.35 | $2.59 | 67.95% | -31.17% |
| Mar 03, 2022 | Steven Mah | Cowen & Co. | $12.00 | $3.86 | 210.88% | 89.87% |
The latest Ginkgo Bioworks stock forecast, released on Aug 23, 2024 by Mark Massaro from BTIG, set a price target of $7.00, which represents a -15.66% decrease from the stock price at the time of the forecast ($8.30), and a 10.76% increase from DNA last price ($6.32).
Ginkgo Bioworks Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $7.00 | $7.00 | $7.00 |
| Last Closing Price | $6.32 | $6.32 | $6.32 |
| Upside/Downside | 10.76% | 10.76% | 10.76% |
In the current month, the average price target of Ginkgo Bioworks stock is $7.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 10.76% increase as opposed to Ginkgo Bioworks's last price of $6.32. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 23, 2024 | BTIG | Sell | Sell | Hold |
| Jun 26, 2024 | BTIG | Sell | Sell | Hold |
| May 15, 2024 | BTIG | Buy | Sell | Downgrade |
| May 10, 2024 | William Blair | - | Underperform | Downgrade |
| Aug 16, 2022 | Raymond James | Outperform | Outperform | Hold |
| Aug 16, 2022 | BTIG | Buy | Buy | Hold |
| Aug 16, 2022 | CLSA | - | Sell | Downgrade |
| Jun 16, 2022 | Jefferies | Buy | Buy | Hold |
| May 18, 2022 | Bank of America Securities | - | Underperform | Downgrade |
| Feb 23, 2022 | Goldman Sachs | - | Neutral | Initialise |
Ginkgo Bioworks's last stock rating was published by BTIG on Aug 23, 2024. The company gave DNA a "Sell" rating, the same as its previous rate.
Ginkgo Bioworks Financial Forecast
Ginkgo Bioworks Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $34.76M | $55.43M | $80.57M | $80.70M | $98.28M | $66.40M | - | $168.41M | $148.49M | - |
| Avg Forecast | $78.40M | $71.60M | $62.00M | $51.00M | $64.27M | $58.47M | $49.66M | $44.94M | $48.66M | $45.35M | $43.14M | $45.97M | $42.50M | $48.08M | $71.50M | $71.73M | $88.64M | $60.35M | $78.83M | $105.67M | $94.81M | $46.00M |
| High Forecast | $81.93M | $74.82M | $64.79M | $53.29M | $67.16M | $61.09M | $51.89M | $46.96M | $50.84M | $46.47M | $45.08M | $48.04M | $54.23M | $50.24M | $74.71M | $74.96M | $92.63M | $63.07M | $78.83M | $112.01M | $100.50M | $48.76M |
| Low Forecast | $76.22M | $69.61M | $60.28M | $49.58M | $62.48M | $56.84M | $48.28M | $43.69M | $47.30M | $44.23M | $41.95M | $44.70M | $35.64M | $46.74M | $69.51M | $69.74M | $86.18M | $58.67M | $78.83M | $101.36M | $90.95M | $44.13M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 1.15% | 1.13% | 1.13% | 1.11% | 1.10% | - | 1.59% | 1.57% | - |
Ginkgo Bioworks's average Quarter revenue forecast for Mar 24 based on 2 analysts is $45.97M, with a low forecast of $44.70M, and a high forecast of $48.04M. DNA's average Quarter revenue forecast represents a 32.28% increase compared to the company's last Quarter revenue of $34.76M (Dec 23).
Ginkgo Bioworks EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-178.12M | $-286.39M | $-184.15M | $-191.62M | $-234.20M | $-654.81M | - | $-684.28M | $-1.57B | - |
| Avg Forecast | $-78.40M | $-71.60M | $-62.00M | $-51.00M | $-64.27M | $-58.47M | $-49.66M | $-44.94M | $-48.66M | $-45.35M | $-43.14M | $-45.97M | $-42.50M | $-48.08M | $-71.50M | $-71.73M | $-88.64M | $-60.35M | $-78.83M | $-4.18B | $-94.81M | $-46.00M |
| High Forecast | $-76.22M | $-69.61M | $-60.28M | $-49.58M | $-62.48M | $-56.84M | $-48.28M | $-43.69M | $-47.30M | $-44.23M | $-41.95M | $-44.70M | $-35.64M | $-46.74M | $-69.51M | $-69.74M | $-86.18M | $-58.67M | $-78.83M | $-3.35B | $-90.95M | $-44.13M |
| Low Forecast | $-81.93M | $-74.82M | $-64.79M | $-53.29M | $-67.16M | $-61.09M | $-51.89M | $-46.96M | $-50.84M | $-46.47M | $-45.08M | $-48.04M | $-54.23M | $-50.24M | $-74.71M | $-74.96M | $-92.63M | $-63.07M | $-78.83M | $-5.02B | $-100.50M | $-48.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 4.19% | 5.96% | 2.58% | 2.67% | 2.64% | 10.85% | - | 0.16% | 16.58% | - |
undefined analysts predict DNA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ginkgo Bioworks's previous annual EBITDA (undefined) of $NaN.
Ginkgo Bioworks Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-211.69M | $-302.89M | $-173.31M | $-204.97M | $-174.15M | $-669.05M | - | $-592.59M | $-1.60B | - |
| Avg Forecast | $-96.00M | $-100.60M | $-107.97M | $-117.53M | $-92.37M | $-109.49M | $-109.03M | $-134.25M | $-118.47M | $-140.80M | $-159.14M | $-171.25M | $-198.65M | $-187.89M | $-177.25M | $-174.65M | $-427.71M | $-537.73M | $-367.14M | $-4.25B | $-81.93M | $-69.22M |
| High Forecast | $-92.53M | $-96.97M | $-104.07M | $-113.29M | $-89.03M | $-105.54M | $-105.09M | $-129.40M | $-114.19M | $-120.69M | $-153.39M | $-165.07M | $-154.51M | $-181.10M | $-170.85M | $-168.34M | $-412.26M | $-518.31M | $-367.14M | $-3.40B | $-77.59M | $-65.55M |
| Low Forecast | $-101.61M | $-106.49M | $-114.28M | $-124.40M | $-97.77M | $-115.89M | $-115.41M | $-142.10M | $-125.40M | $-160.92M | $-168.45M | $-181.26M | $-242.80M | $-198.87M | $-187.61M | $-184.86M | $-452.72M | $-569.17M | $-367.14M | $-5.10B | $-88.33M | $-74.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.61% | 0.98% | 1.17% | 0.41% | 1.24% | - | 0.14% | 19.59% | - |
Ginkgo Bioworks's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DNA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Ginkgo Bioworks SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $89.22M | $82.03M | $102.34M | $111.43M | $121.42M | $435.18M | - | $434.77M | $781.63M | $28.96M |
| Avg Forecast | $124.44M | $113.65M | $98.41M | $80.95M | $102.01M | $92.80M | $78.82M | $71.33M | $77.23M | $71.98M | $68.48M | $72.97M | $67.46M | $76.31M | $113.48M | $113.85M | $140.69M | $95.79M | $125.13M | $167.71M | $150.49M | $31.85M |
| High Forecast | $130.03M | $118.76M | $102.83M | $84.59M | $106.60M | $96.97M | $82.36M | $74.54M | $80.70M | $73.75M | $71.56M | $76.25M | $86.07M | $79.74M | $118.59M | $118.97M | $147.02M | $100.10M | $125.13M | $177.78M | $159.52M | $38.23M |
| Low Forecast | $120.98M | $110.49M | $95.67M | $78.70M | $99.17M | $90.22M | $76.63M | $69.35M | $75.08M | $70.20M | $66.58M | $70.94M | $56.56M | $74.19M | $110.33M | $110.69M | $136.79M | $93.13M | $125.13M | $160.88M | $144.36M | $25.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.07% | 0.90% | 0.98% | 0.86% | 4.54% | - | 2.59% | 5.19% | 0.91% |
Ginkgo Bioworks's average Quarter SG&A projection for Mar 24 is $72.97M, based on 2 Wall Street analysts, with a range of $70.94M to $76.25M. The forecast indicates a -18.22% fall compared to DNA last annual SG&A of $89.22M (Dec 23).
Ginkgo Bioworks EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.13 | $-0.19 | $-0.09 | $-0.11 | $-0.09 | $-0.41 | - | $-0.37 | $-1.05 | $-0.08 |
| Avg Forecast | $-1.87 | $-1.96 | $-2.10 | $-2.29 | $-1.80 | $-2.13 | $-2.12 | $-2.61 | $-2.31 | $-2.74 | $-3.10 | $-3.33 | $-3.87 | $-3.66 | $-3.45 | $-3.40 | $-8.33 | $-10.47 | $-0.18 | $-0.21 | $-0.04 | $-0.04 |
| High Forecast | $-1.80 | $-1.89 | $-2.03 | $-2.21 | $-1.73 | $-2.05 | $-2.05 | $-2.52 | $-2.22 | $-2.35 | $-2.99 | $-3.21 | $-3.01 | $-3.53 | $-3.33 | $-3.28 | $-8.02 | $-10.09 | $-0.18 | $-0.20 | $-0.04 | $-0.03 |
| Low Forecast | $-1.98 | $-2.07 | $-2.22 | $-2.42 | $-1.90 | $-2.26 | $-2.25 | $-2.77 | $-2.44 | $-3.13 | $-3.28 | $-3.53 | $-4.73 | $-3.87 | $-3.65 | $-3.60 | $-8.81 | $-11.08 | $-0.18 | $-0.23 | $-0.04 | $-0.04 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 0.05% | 0.03% | 0.03% | 0.01% | 0.04% | - | 1.73% | 25.34% | 2.29% |
According to undefined Wall Street analysts, Ginkgo Bioworks's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DNA previous annual EPS of $NaN (undefined).
DNA Forecast FAQ
Is Ginkgo Bioworks a good buy?
Yes, according to 5 Wall Street analysts, Ginkgo Bioworks (DNA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of DNA's total ratings.
What is DNA's price target?
Ginkgo Bioworks (DNA) average price target is $7.34 with a range of $4.35 to $12, implying a 16.14% from its last price of $6.32. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ginkgo Bioworks stock go up soon?
According to Wall Street analysts' prediction for DNA stock, the company can go up by 16.14% (from the last price of $6.32 to the average price target of $7.34), up by 89.87% based on the highest stock price target, and down by -31.17% based on the lowest stock price target.
Can Ginkgo Bioworks stock reach $9?
DNA's highest twelve months analyst stock price target of $12 supports the claim that Ginkgo Bioworks can reach $9 in the near future.
What is Ginkgo Bioworks's current price target trend?
1 Wall Street analyst forecast a $7 price target for Ginkgo Bioworks (DNA) this month, up 10.76% from its last price of $6.32. Compared to the last 3 and 12 months, the average price target increased by 10.76% and increased by 10.76%, respectively.
What are Ginkgo Bioworks's analysts' financial forecasts?
Ginkgo Bioworks's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $217.33M (high $227.1M, low $211.29M), average EBITDA is $-217M (high $-211M, low $-227M), average net income is $-445M (high $-429M, low $-471M), average SG&A $344.95M (high $360.46M, low $335.37M), and average EPS is $-8.665 (high $-8.352, low $-9.171). DNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $263M (high $274.83M, low $255.69M), average EBITDA is $-263M (high $-256M, low $-275M), average net income is $-422M (high $-407M, low $-447M), average SG&A $417.44M (high $436.21M, low $405.84M), and average EPS is $-8.216 (high $-7.919, low $-8.696).
Did the DNA's actual financial results beat the analysts' financial forecasts?
Based on Ginkgo Bioworks's last annual report (Dec 2023), the company's revenue was $251.46M, beating the average analysts forecast of $233.81M by 7.55%. Apple's EBITDA was $-864M, beating the average prediction of $-234M by 269.71%. The company's net income was $-893M, beating the average estimation of $-738M by 20.91%. Apple's SG&A was $385.02M, beating the average forecast of $371.1M by 3.75%. Lastly, the company's EPS was $-0.56, missing the average prediction of $-14.373 by -96.10%. In terms of the last quarterly report (Dec 2023), Ginkgo Bioworks's revenue was $34.76M, missing the average analysts' forecast of $42.5M by -18.23%. The company's EBITDA was $-178M, beating the average prediction of $-42.502M by 319.08%. Ginkgo Bioworks's net income was $-212M, beating the average estimation of $-199M by 6.56%. The company's SG&A was $89.22M, beating the average forecast of $67.46M by 32.26%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-3.867 by -96.64%